undamentalytics Newsletter

El-Hibri Fuad: insider trades

Officer, Director at 2 companies we cover. 8 open-market purchases and 3 sales not made under a pre-set plan, reported from December 3, 2012 to August 13, 2019.

Would copying El-Hibri Fuad’s purchases have beaten the S&P 500?

Too few purchases to judge. None of their purchases has 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. After their sales, the shares moved +29.1% against the index over 12 months on average (a negative figure means selling was the right call); 0% trailed it. None of their purchases could be priced, so there is no copy portfolio.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

El-Hibri Fuad: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 3 −5.5% −10.0% 67% 2 — — Not enough years
Sales, 12 months after the report 3 +29.1% +18.6% 0% 2 — — Not enough years
Sales, 12 months after the trade 3 +27.8% +19.9% 0% 2 — — Not enough years

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Aptevo Therapeutics Inc. APVO Board of Directors80July 11, 2019August 13, 2019
Emergent Biosolutions Inc. EBS Chairman03December 3, 2012April 19, 2013

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
August 13, 2019August 12, 2019 APVO Purchase $76,000 not yetnot yetnot yet
July 30, 2019July 29, 2019 APVO Purchase $45,662 not yetnot yetnot yet
July 23, 2019July 22, 2019 APVO Purchase $26,700 not yetnot yetnot yet
July 19, 2019July 19, 2019 APVO Purchase $23,814 not yetnot yetnot yet
July 18, 2019July 18, 2019 APVO Purchase $12,531 not yetnot yetnot yet
July 18, 2019July 17, 2019 APVO Purchase $16,648 not yetnot yetnot yet
July 12, 2019July 11, 2019 APVO Purchase $12,487 not yetnot yetnot yet
July 11, 2019July 10, 2019 APVO Purchase $16,081 not yetnot yetnot yet
April 19, 2013April 17, 2013 EBS Sale $1,727,263 +8.0%+53.1%+44.8%
December 6, 2012December 4, 2012 EBS Sale $649,405 −14.4%+15.5%+18.7%
December 3, 2012November 30, 2012 EBS Sale $861,650 −10.0%+18.7%+19.9%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why El-Hibri Fuad traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.